• News
• Science
• AUTHOR: codevision AI engine
• Wired Science

Weight-loss drug Zepbound, containing the active ingredient tirzepatide, is being tested as a potential treatment for long Covid. This trial, sponsored by Scripps Research, aims to evaluate its anti-inflammatory effects and ability to improve symptoms like fatigue and brain fog. The study is fully remote, allowing participants to receive the drug by mail and track their progress through wearable devices. The remote design ensures that even those who are housebound or bedbound can take part, addressing a major challenge in long Covid research. The drug has already shown promise in reducing inflammation and improving metabolic health, which makes it a compelling candidate for treating long Covid.

Key facts

• Zepbound, which contains tirzepatide, is being tested as a treatment for long Covid due to its potential anti-inflammatory effects.
• The Scripps Research trial is fully remote, enabling participants to receive the drug by mail and track their health through wearable devices.
• Long Covid affects up to 20 million people in the US, with symptoms such as fatigue, brain fog, and body aches.
• Researchers believe that tirzepatide may reduce chronic inflammation, which is thought to be a key factor in long Covid.
• Microdosing of tirzepatide has shown significant improvements in symptoms for some long Covid patients, according to preliminary studies.